For US residents only.

“I’m taking charge.”

Ask your health care provider about ZYKADIA® (ceritinib) when you are diagnosed with ALK-positive metastatic NSCLC.

Important Safety Information:

What is the most important information I should know about ZYKADIA?

ZYKADIA may cause serious side effects, such as:

  • Stomach and intestinal (gastrointestinal) problems ZYKADIA may cause stomach and inte...
See More
Approved Use:

What is ZYKADIA?

ZYKADIA® (ceritinib) capsules is a prescription medicine that is used to treat people with non-small cell lung cancer (NSCLC) that:

    • Is caused by a defect in a gene called anaplastic lymphoma kinase (ALK) and has spread to other parts of the body

It is not known if ZYKADIA is safe and effective in children....



ZYKADIA® (ceritinib) was studied in ALK+ metastatic NSCLC in 2 clinical trials. One trial looked at patients who were taking it as their first treatment. The other trial looked at patients who were switching to ZYKADIA after receiving a different targeted treatment.



If you or someone you love is starting ZYKADIA, there are resources available to help you. Find out about financial support, the co-pay card, and other useful programs here.

Learn More